Viridian Stock Plummets 40% Despite Positive Trial Data

VRDN Shares Fall Despite Successful Drug Trial

Viridian Therapeutics stock (NASDAQ:VRDN) plummeted 40% on Monday. This decline occurred despite the company reporting that its Phase 3 REVEAL-1 trial for elegrobart, a treatment for active thyroid eye disease, successfully met its primary endpoint with high statistical significance.

Clinical Trial Overview

The REVEAL-1 trial demonstrated strong results. Proptosis responder rates were 54% for the every-four-weeks dosing and 63% for the every-eight-weeks dosing, compared to just 18% for placebo. The drug was also well-tolerated with low rates of hearing-related side effects, which were limited to tinnitus.

Unexpected Market Response and Future Outlook

Despite the trial's success, the market responded negatively. Viridian Therapeutics plans to submit a Biologics License Application to the FDA in the first quarter of 2027. The company's second Phase 3 trial, REVEAL-2, is expected to have results in the second quarter of 2026.

Summary

Viridian Therapeutics presented positive clinical data for its lead drug candidate but experienced a significant stock price drop. Investors will be watching the progress of its regulatory submissions and upcoming trial results for further direction.

FAQ

Q: Why did Viridian Therapeutics stock drop despite a successful trial?
A: The source does not specify the exact reason for the market's negative reaction but highlights the contrast between the positive clinical results and the sharp stock decline.

Q: What is the next major catalyst for Viridian Therapeutics?
A: The company expects topline results from its second Phase 3 trial, REVEAL-2, in the second quarter of 2026 and plans an FDA submission in the first quarter of 2027.

Source: Investing.com